glp-1 drugs for parkinson's disease Are we measuring the wrong primary outcome for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep If GLP-1 Drugs Are Good
Description
de Souza, G.A
Early preclinical and small-scale human studies suggest these drugs may influence brain reward pathways involved in addictive behaviours, potentially reducing alcohol cravings and intake
After 6 weeks, patients were then randomized to IGlarLixi or glargine
This is a built-in safety mechanism that distinguishes GLP-1 receptor agonists from older diabetes medications
Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems
Moreover, a greater proportion of participants on retatrutide 8 and 12 mg (7782%) achieved an HbA1c 6.5% compared to placebo (5%) and dulaglutide 1.5 mg (43%)
